BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• 20 years or older

• Japanese male or female

• Non- valvular atrial fibrillation documented by ECG

• Patients aged 60 years and older or with a risk of stroke

Exclusion Criteria:

• Prior stroke and TIA

• Patients in whom anticoagulants are contraindicated